<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01890200</url>
  </required_header>
  <id_info>
    <org_study_id>TCM-700-02-01</org_study_id>
    <nct_id>NCT01890200</nct_id>
  </id_info>
  <brief_title>The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)</brief_title>
  <official_title>A Phase III, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effects of Adding TCM-700C,Botanical Drug, on the Standard Treatment (Peginterferon and Ribavirin) for Subjects With Naive Genotype 1 Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TCM Biotech International Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TCM Biotech International Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, multi-center, placebo controlled, three parallel arms,&#xD;
      Phase IIb/III clinical study to evaluate the effects of adding a TCM-700C with a low or high&#xD;
      dose onto the combination treatment (PegIFN plus RBV) for subjects with naive genotype 1 HCV&#xD;
      infection.&#xD;
&#xD;
      This will be demonstrated by a higher sustained virologic response rate, defined as the&#xD;
      absence of detectable HCV RNA 24 weeks after the termination of combination treatment,&#xD;
      compared with the placebo add-on.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects with written informed consent will be stratified according to their&#xD;
      baseline HCV RNA (≤800,000 IU/mL versus&gt;800,000 IU/mL), stage of liver fibrosis (METAVIR&#xD;
      system fibrosis score of 0 1 versus 2 3).&#xD;
&#xD;
      During the 48 week Treatment Period and 24 week Follow up Period, subjects will be assessed&#xD;
      at regular intervals for efficacy and safety at Weeks 2, 4, 8, 12, 16 and then every 8 weeks&#xD;
      thereafter until study completion. If possible, subjects who prematurely discontinue the&#xD;
      study during the Treatment Period will have samples taken for hematology, biochemistry and&#xD;
      urinalysis in the same week of discontinuation as well as 24 weeks after discontinuation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sustained virologic response (SVR) rate</measure>
    <time_frame>24 weeks after the end of treatment (EOT, 48 weeks)</time_frame>
    <description>undetectable HCV RNA 24 weeks after the EOT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virologic response (VR)</measure>
    <time_frame>at the EOT (48 weeks)</time_frame>
    <description>undetectable HCV RNA at the EOT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
    <time_frame>24 weeks after the EOT</time_frame>
    <description>undetectable HCV RNA at the EOT followed by a positive HCV RNA level within 24 weeks after the EOT</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>TCM-700C (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCM-700C (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo add on(t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>conventional treatment of Hepatitis C</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TCM-700C (high dose)</arm_group_label>
    <arm_group_label>TCM-700C (low dose)</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>conventional treatment of Hepatitis C</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TCM-700C (high dose)</arm_group_label>
    <arm_group_label>TCM-700C (low dose)</arm_group_label>
    <other_name>Rebetol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCM-700C</intervention_name>
    <description>An add-on drug to conventional treatment of Hepatitis C</description>
    <arm_group_label>TCM-700C (high dose)</arm_group_label>
    <arm_group_label>TCM-700C (low dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, without acting ingredient.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo, without acting ingredient.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult subjects who are 20 to 65 years old (inclusive), of either gender and in any&#xD;
             ethnical group in Asia.&#xD;
&#xD;
          -  Chronic hepatitis C, positive with both antibody to hepatitis C virus (anti HCV) and&#xD;
             HCV RNA assays.&#xD;
&#xD;
          -  Confirmed HCV genotype 1.&#xD;
&#xD;
          -  Subjects who are indicated to have combination treatment of PegIFNα 2a and RBV at the&#xD;
             discretion of the investigator.&#xD;
&#xD;
          -  All fertile males and females receiving RBV must be using two forms of effective&#xD;
             contraception during treatment with study drugs and 6 months post treatment&#xD;
             completion.&#xD;
&#xD;
          -  Subjects must voluntarily give written informed consent indicating that they&#xD;
             understand the purpose of and procedures required for the study and are willing to&#xD;
             participate in the study.&#xD;
&#xD;
          -  Subjects must be able to comply with the assessments during the study.&#xD;
&#xD;
          -  Subjects must be able to understand study QoL questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with any IFN α or any medicines that contain Cordyceps.&#xD;
&#xD;
          -  Prior treatment of hepatitis C with any other antiviral or immune modulators.&#xD;
&#xD;
          -  Investigational therapy administered within 4 weeks, or within a time interval less&#xD;
             than at least 5 half lives of the investigational agent, whichever is longer, prior to&#xD;
             the first scheduled day of dosing in this study.&#xD;
&#xD;
          -  Subjects diagnosed with hepatocellular carcinoma (HCC) by biopsy or α fetoprotein&#xD;
             (AFP) serology and radiology (helical computed tomography [CT] and/or magnetic&#xD;
             resonance imaging [MRI]) within 5 years of signing the informed consent form.&#xD;
&#xD;
          -  Evidence of hepatic decompensation (history or current evidence of ascites, bleeding&#xD;
             varices or hepatic encephalopathy).&#xD;
&#xD;
          -  History or evidence of other liver diseases other than chronic HCV infection.&#xD;
&#xD;
          -  Subjects with known allergy or hypersensitivity to any ingredient of the study drug or&#xD;
             placebo.&#xD;
&#xD;
          -  Pregnant, planning on becoming pregnant, or breastfeeding female subject or male&#xD;
             subject whose partner is pregnant or planning on becoming pregnant.&#xD;
&#xD;
          -  Subject with any of the following laboratory abnormalities:&#xD;
&#xD;
               1. Platelet count &lt;90,000/mm3;&#xD;
&#xD;
               2. Absolute neutrophil count &lt;1500 cells/mm3;&#xD;
&#xD;
               3. Hemoglobin &lt;12 g/dL for women and &lt;13 g/dL for men;&#xD;
&#xD;
               4. Creatinine &gt;1.5 mg/dL;&#xD;
&#xD;
               5. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt;10 x&#xD;
                  upper limit of normal (ULN);&#xD;
&#xD;
               6. Total serum bilirubin &gt;1.5 x ULN;&#xD;
&#xD;
               7. Subjects without cirrhosis and AFP &gt;50 ng/mL must have an ultrasound between the&#xD;
                  screening and baseline visit with no findings suspicious for HCC.&#xD;
&#xD;
          -  Medical conditions which are contraindications for PegIFNα 2a or RBV therapy:&#xD;
&#xD;
               1. Psychiatric disorders;&#xD;
&#xD;
               2. Organ transplant (other than cornea or hair transplant or skin graft);&#xD;
&#xD;
               3. Severe concurrent medical disease such as severe hypertension, significant&#xD;
                  coronary heart disease, poorly controlled diabetes mellitus (glycated hemoglobin&#xD;
                  A1c [HbA1c] &gt;8.5%), not adequately controlled thyroid dysfunction, chronic&#xD;
                  obstructive pulmonary disease, severe infections (bacterial, viral, fungal,&#xD;
                  including acute tuberculosis), or hemoglobinopathies (thalassemia major or sickle&#xD;
                  cell anemia);&#xD;
&#xD;
               4. Autoimmune hepatitis or other autoimmune conditions known to be exacerbated by&#xD;
                  PegIFNα 2a and RBV.&#xD;
&#xD;
          -  History of a severe seizure disorder or current anticonvulsant use.&#xD;
&#xD;
          -  Evidence of severe retinopathy (e.g., cytomegalovirus retinitis, macular degeneration)&#xD;
             or clinically relevant ophthalmological disorder (e.g., due to diabetes mellitus or&#xD;
             hypertension).&#xD;
&#xD;
          -  Other cases judged by the investigator to be ineligible for participation in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>I-Shyan Sheen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lai Wei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University People's Hospit</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>June 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2013</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>add-on treatment</keyword>
  <keyword>botanical drug</keyword>
  <keyword>HCV genotype 1</keyword>
  <keyword>TCM-700C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

